EMBC * Stock Overview
A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Embecta Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$497.96 |
| 52 Week High | US$666.36 |
| 52 Week Low | US$497.96 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -9.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMBC * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -9.1% | 0% | 0% |
Return vs Industry: EMBC * underperformed the MX Medical Equipment industry which returned -2.1% over the past year.
Return vs Market: EMBC * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| EMBC * volatility | |
|---|---|
| EMBC * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: EMBC * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EMBC *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 1,900 | Dev Kurdikar | www.embecta.com |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing patient’s diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
Embecta Corp. Fundamentals Summary
| EMBC * fundamental statistics | |
|---|---|
| Market cap | Mex$20.30b |
| Earnings (TTM) | Mex$802.88m |
| Revenue (TTM) | Mex$18.94b |
25.3x
P/E Ratio1.1x
P/S RatioIs EMBC * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBC * income statement (TTM) | |
|---|---|
| Revenue | US$1.11b |
| Cost of Revenue | US$368.50m |
| Gross Profit | US$745.00m |
| Other Expenses | US$697.80m |
| Earnings | US$47.20m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 66.91% |
| Net Profit Margin | 4.24% |
| Debt/Equity Ratio | -198.2% |
How did EMBC * perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield72%
Payout RatioDoes EMBC * pay a reliable dividends?
See EMBC * dividend history and benchmarks| Embecta dividend dates | |
|---|---|
| Ex Dividend Date | Aug 24 2023 |
| Dividend Pay Date | Sep 13 2023 |
| Days until Ex dividend | 499 days |
| Days until Dividend pay date | 479 days |
Does EMBC * pay a reliable dividends?
See EMBC * dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/13 19:51 |
| End of Day Share Price | 2023/05/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Embecta Corp. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Marie Thibault | BTIG |